Diamond-Blackfan anemia is a rare hereditary disorder belonging to the group of congenital erythroblastopenias, characterized by a selective failure of red blood cell production in the bone marrow. It typically presents during the first year of life with severe macrocytic anemia and reticulocytopenia, in a context of normal white blood cell and platelet counts.
Although primarily a hematologic disease, Diamond-Blackfan anemia is often associated with congenital malformations and, in some cases, an increased risk of hematologic and solid tumors in adulthood. Early recognition and appropriate management are crucial to improving survival and quality of life.
Diamond-Blackfan anemia is caused by genetic mutations primarily affecting genes encoding ribosomal proteins (e.g., RPS19, RPL5, RPL11). These mutations impair the proper assembly of ribosomes, which are essential for protein synthesis and cellular proliferation.
Ribosomal dysfunction leads to nucleolar stress in hematopoietic cells, activating the p53 pathway and causing early apoptosis of erythroid precursors. This selective loss of the erythroid lineage clinically manifests as isolated anemia, while granulocytes and megakaryocytes are generally spared.
Genotypic variability results in a wide phenotypic heterogeneity: some patients present only with anemia, while others exhibit multiple congenital anomalies, including:
Long-term oncologic risks include leukemia, myelodysplastic syndromes, and solid tumors (especially osteosarcoma and colorectal cancer).
The medical history should focus on:
The typical clinical presentation includes:
In some cases, anemia may be incidentally detected during routine pediatric examinations or neonatal screenings.
The diagnostic suspicion arises in an infant presenting with isolated macrocytic anemia, normal white blood cell and platelet counts, with or without associated congenital anomalies.
The rational diagnostic approach includes:
Confirm the selective absence of erythroid precursors, with preserved maturation of the other hematopoietic lineages.
Typically elevated as a compensatory response to hypoproliferative anemia.
Identification of mutations in ribosomal protein genes (RPS19, RPL5, RPL11, etc.) confirms the diagnosis and allows for family genetic counseling.
Diamond-Blackfan anemia must be distinguished from other causes of macrocytic hypoproliferative anemia in children, such as:
The combination of isolated anemia, reticulocytopenia, absence of erythroid precursors in the marrow, and a specific genetic mutation is decisive for a definitive diagnosis.
The treatment of Diamond-Blackfan anemia is based on a progressive and individualized approach:
Glucocorticoids (prednisone or prednisolone) are the first-line therapy, with a positive response observed in approximately 70–80% of patients. Steroid therapy is initiated at low doses and gradually tapered to minimize side effects.
Indicated in patients who are nonresponsive to steroids or have contraindications to their use. Regular transfusion therapy requires careful management of iron overload with chelation therapy.
In severe or refractory cases, especially in the presence of high-risk mutations or progression to myelodysplastic syndromes, allogeneic transplantation from a compatible donor is indicated, offering a potential definitive cure.
Innovative drugs that modulate ribosomal synthesis or agents that stimulate erythroid proliferation (e.g., luspatercept) are under investigation and represent potential future therapeutic alternatives.
The prognosis of Diamond-Blackfan anemia is highly variable:
A multidisciplinary integrated approach significantly improves patient survival and overall well-being.
The main complications associated with Diamond-Blackfan anemia include:
Regular hematologic and oncologic monitoring is essential for optimal long-term management.